NCT07556822招募中1 期
An Open-Label, Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HRS-3005 in Patients With B-cell Malignancies
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 190
- 试验地点
- 1
研究概览
简要总结
The study is being conducted to evaluate the safety and tolerability of HRS-3005. To explore the Maximum Tolerated Dose (MTD, if possible) and the Recommended Phase 2 Dose (RP2D). This study also preliminarily evaluated the efficacy of HRS-3005 in patients with B-cell malignancy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years;
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
- •Life expectancy ≥12 weeks;
- •Histologically or cytologically confirmed relapsed/refractory B-cell malignancies;
- •Measurable disease;
- •Adequate organ function;
- •Females of childbearing potential must not be pregnant or lactating. Females of childbearing potential and males with partners of childbearing potential must agree to use effective contraception from the time of informed consent until 28 days after the last dose of study treatment;
- •Voluntary participation with signed informed consent, good compliance, and willingness to complete follow-up visits.
排除标准
- •Known central nervous system (CNS) involvement by malignancy;
- •History of other malignancy within 2 years prior to first dose of study drug, except for the disease under study;
- •Prior autologous stem cell transplantation or CAR-T therapy within 12 weeks before first dose of study drug;
- •Prior allogeneic hematopoietic stem cell transplantation;
- •Positive hepatitis B surface antigen (HBsAg) with detectable HBV-DNA at screening;
- •Positive hepatitis C antibody with detectable HCV-RNA at screening;
- •Positive HIV antigen/antibody test at screening;
- •Active fungal, bacterial, and/or viral infection requiring systemic therapy;
- •Major surgery or significant trauma within 28 days prior to first dose of study drug;
- •Severe disease of major organ systems;
- •Prior anti-tumor treatment-related adverse events not recovered to ≤Grade 1 or stable status;
- •Incomplete washout period from prior anti-tumor therapy before first dose of study drug;
- •Use of strong or moderate CYP3A inducers, or strong or moderate CYP3A inhibitors within 14 days prior to first dose of study drug;
- •Live vaccine administration within 28 days prior to first dose of study drug;
- •Ongoing alcohol or drug abuse;
- •Intracranial hemorrhage within 6 months prior to first dose of study drug;
- •Currently receiving vitamin K antagonists or Factor Xa inhibitors;
- •History of severe bleeding disorder, such as coagulation factor deficiency or von Willebrand factor (vWF) deficiency;
- •Inability to swallow oral medication, or presence of severe gastrointestinal disease or prior surgery significantly affecting gastrointestinal function;
- •Pregnant or lactating females;
- •Concurrent participation in another interventional clinical study, or less than 1 month between signing informed consent and last dose of previous clinical study.
研究组 & 干预措施
Treatment group A: HRS-3005
Experimental
干预措施: HRS-3005 (Drug)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Phase I Study of HRS-1635 in B-cell MalignanciesNCT07583212Chengdu Suncadia Medicine Co., Ltd.180
已完成
不适用
Safety Evaluation of HORS-051511 in Healthy AdultsCTRI/2023/12/060476Himalaya Wellness Company (HWC)12
招募中
1 期
A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive/HER2-Negative CancerBreast CancerNCT07358377Atridia Pty Ltd.15
尚未招募
2 期
A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous UrticariaNCT07613866Chengdu Suncadia Medicine Co., Ltd.190
招募中
2/3 期
Study of HSSH-062501 Tablets in People with Mild to Moderate Chronic Joint PainCTRI/2025/11/097144Himalaya Wellness Company300